Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Vicinium Elicits Promising Responses in BCG-Unresponsive Bladder Cancer

August 13th 2019

Vicinium led to 6- and 12-month complete response rates in patients with high-risk non-muscle invasive bladder cancer who did not respond to Bacillus Calmette-Guérin therapy, according to updated results of the phase III VISTA trial.

Distinguishing Between Frontline Monotherapies and Combos in mRCC

August 12th 2019

Richard W. Joseph, MD, discusses the factors that must be considered when selecting the appropriate frontline treatment for patients with metastatic renal cell carcinoma, the need for clarity regarding the role of cytoreductive nephrectomy, as well as the research that is being done in those with rarer subtypes of kidney cancer.

Dr. Thiel on Resectability in mRCC

August 10th 2019

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses resectability in metastatic renal cell carcinoma (mRCC).

Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCC

August 5th 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).

Dr. Thiel on Overall Survival Data From the CARMENA Trial in mRCC

August 2nd 2019

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the phase III randomized CARMENA trial, which examined cytoreductive nephrectomy plus sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma.

Dr. Singh on the Prevalence of Genomic Testing in Urothelial Cancer

August 1st 2019

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the prevalence of genomic testing in urothelial cancer.

Advances and Challenges Faced in the Treatment of mRCC

July 29th 2019

Biomarkers: Guide to Clinical Decision Making to Treat mRCC

July 29th 2019

NKTR-214 and COSMIC-313 for Previously Untreated RCC

July 29th 2019

Ongoing Clinical Trials for Metastatic RCC

July 29th 2019

Third-Line Therapy and Beyond in Treating Metastatic RCC

July 29th 2019

Safety and Tolerability Influence the Use of TKIs in RCC

July 29th 2019

Tyrosine Kinase Inhibitors Used Alone or in Combination to Treat RCC

July 29th 2019

Factors Influencing Choice of Sequential Therapy in RCC

July 29th 2019

Patient-Reported Outcomes for RCC Treatment Therapies

July 29th 2019

Role of Risk Stratification in Treatment Planning for mRCC

July 29th 2019

NCCN Guideline Changes for First- & Beyond-First-Line RCC Therapy

July 29th 2019

Cytoreductive Nephrectomy in Metastatic RCC

July 29th 2019

CheckMate 214 Trial for Newly Diagnosed Metastatic RCC

July 29th 2019

Additive and Overlapping Adverse Effects of RCC Therapy

July 29th 2019